Compare ASR & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASR | ALKS |
|---|---|---|
| Founded | 1996 | 1987 |
| Country | Mexico | Ireland |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 8.7B |
| IPO Year | 2001 | 2012 |
| Metric | ASR | ALKS |
|---|---|---|
| Price | $238.58 | $40.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $365.00 | $43.43 |
| AVG Volume (30 Days) | 43.9K | ★ 1.7M |
| Earning Date | 04-22-2026 | 05-05-2026 |
| Dividend Yield | ★ 12.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,475,899,000.00 |
| Revenue This Year | $7.44 | $24.26 |
| Revenue Next Year | $9.69 | $4.47 |
| P/E Ratio | $18.58 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $235.79 | $27.00 |
| 52 Week High | $381.52 | $55.67 |
| Indicator | ASR | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 24.56 | N/A |
| Support Level | N/A | N/A |
| Resistance Level | $314.70 | N/A |
| Average True Range (ATR) | 5.17 | 0.00 |
| MACD | -0.61 | 0.00 |
| Stochastic Oscillator | 8.08 | 0.00 |
Grupo Aeroportuario del Sureste SAB de CV and its subsidiaries hold concessions to operate, maintain, and develop airports in the southeast region of Mexico. As an operator of airports, it charges airlines, passengers, and other users fees for using the airports' facilities. The group also derives rental and other income from commercial activities conducted at its airports, such as the leasing of space to restaurants and retailers. The company's operating segments are Cancun, which generates majority revenue, Aerostar, Airplan, Merida, Villahermosa, Holding and Services, and Others.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.